Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

January 2019

Lumoxiti Now Covered with Prior Authorization


In September, the Food and Drug Administration approved the drug Lumoxiti for the treatment of adult patients with relapsed or refractory hairy cell leukemia. Effective immediately, Harvard Pilgrim will provide coverage for commercial members for Lumoxiti (moxetumomab pasudotox-tdfk) with prior authorization from CVS Health—NovoLogix, when all of the following criteria are met:

  • The patient has received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
  • The patient has not previously received 6 or more cycles of treatment with Lumoxiti.

Please use the unlisted code J3590 (unclassified biologics) when billing for the use of Lumoxiti. (For information on billing unlisted codes, please refer to the Injectable and Implantable Drugs Payment Policy.) To request authorization, please contact CVS Health–NovoLogix via phone (844-387-1435) or fax (844-851-0882).

For complete information, please refer to Harvard Pilgrim’s new Lumoxiti Prior Authorization Policy and the associated prior authorization request form, which you can you can find on the Medical Drug Prior Authorization page in the Provider section of Harvard Pilgrim’s website.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

HPHConnect for Providers Getting a New Look in 2019

2019 Quality Grant Applications Due by Feb. 15

HEDIS 2019 Coming Soon: Your Cooperation is Crucial

HPI to Administer BMC HealthNet Plan

Behavioral Health: Services for Improved Access

CLINICIAN CORNER

New Opioid Safety Edits for 2019 Medicare Advantage Plans

Medical Policy Update: Tumor Treating Fields

Reminder: Formulas and Enteral Nutrition Require Prior Authorization

Updates to Proton Beam Therapy Medical Policy

Lumoxiti Now Covered with Prior Authorization

TriVisc and Jivi Now Covered with Prior Authorization

Pharmacy and Therapeutics Committee Meeting Update

OFFICE ASSISTANT

Coding Program Launching in January for Medicare Advantage

PUBLICATION INFORMATION

Robert Farias,
Senior Vice President, Corporate Network Strategy

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator